Kite Pharma, Inc. drugs

2 results

  • tecartus

    (brexucabtagene autoleucel)
    Kite Pharma, Inc.
    TECARTUS is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma and B-cell precursor acute lymphoblastic leukemia. Its approval is based on response rates, with continued approval contingent on further validation of clinical benefit.

  • yescarta

    (axicabtagene ciloleucel)
    Kite Pharma, Inc.
    YESCARTA is indicated for adult patients with refractory or relapsed large B-cell lymphoma after first-line treatment or following two or more therapies. It also treats relapsed or refractory follicular lymphoma after two or more lines of systemic therapy, although approval for follicular lymphoma is contingent on further studies.